ESH Video

#ESHCLL2024 STARTS IN 3 WEEKS, REGISTER NOW!

February 14, 2024

 

3rd Translational Research Conference

CHRONIC LYMPHOCYTIC LEUKAEMIA

 

March 8-10, 2024

Vienna, Austria

#ESHCLL2024

Chairs: Jennifer Brown, Paolo Ghia, Michael Hallek

 


 

The CLL conference will start on March 8th,
only 3 weeks to go!
NOW IS THE TIME TO REGISTER:

 


 


 

About the Conference:

The 3rd ESH Tranlational Research Conference on CHRONIC LYMPHOCYTIC LEUKAEMIA is proposing a programme of leading-edge basic and clinical science where a panel of global experts in the field will provide numerous opportunities for formal and informal interactions to discuss the present and the future of CLL research. It is open to an international audience of biologists and clinicians, particularly welcoming those in-training.

This translational research conference will explore the most recent advances in the understanding of the pathogenesis and clinical management of the disease.  Open and spirited discussion on the most up-to-date information in the field is expected to understand how the many new biologic insights apply to the future of CLL.

 


 

Meet the faculty members:

 


 

CONFERENCE'S MAIN SCIENTIFIC TOPICS:

• CLL disease progression
• Richters syndrome
• Biomarkers: where do we stand?
• Targeting the microenvironment in CLL
• What is the best time-limited therapy
• BTK inhibitors
• Small molecule resistance
• Next generation therapies
• The future: other targets

 


The programme will include:
Plenary Sessions - Simultaneous Meet the Experts Sessions - Brief Oral Communications
Mentored Poster Walk - Ample time for in-depth discussion.

 

 

This educational conference has been approved for 17 CME-CPD credit points
by the European Board for Accreditation in Haematology (EBAH)!

 

For more information, click here!

 


 

With the support of*:


Major Conference Partner
*******


Level 1 Conference Partner
*******

*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.